No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMLX240816P8000
- 2.45
- 0.000.00%
15min DelayClose Mar 4 09:30 ET
0.00High0.00Low
2.45Open2.45Pre Close0 Volume17 Open Interest8.00Strike Price0.00Turnover301.17%IV-180.30%PremiumAug 16, 2024Expiry Date6.02Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9204Delta0.1103Gamma0.33Leverage Ratio-0.0039Theta-0.0026Rho-0.30Eff Leverage0.0008Vega
Intraday
- 5D
- Daily
News
Balancing Potential and Uncertainty: Hold Rating on Amylyx Pharmaceuticals Post-Avexitide Acquisition
Analyst Ratings For Amylyx Pharma
Analysts' ratings for Amylyx Pharma (NASDAQ:AMLX) over the last quarter vary from bullish to bearish, as provided by 5 analysts.The following table summarizes their recent ratings, shedding light on
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper
Express News | Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 46.2% and a total average
Amylyx Pharmaceuticals: Holding Steady Amidst Expansion and Market Skepticism
Comments
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist Avexitide.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
3
$Amylyx Pharmaceuticals(AMLX.US$ let's go 🚶♀️
1
$Amylyx Pharmaceuticals(AMLX.US$ Appears that people like that after that failure, they have acquired a new drug for their sparce pipeline that’s actually in late stage of testing!
1
Read more